438 related articles for article (PubMed ID: 29150421)
1. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Facon T; Dimopoulos MA; Dispenzieri A; Catalano JV; Belch A; Cavo M; Pinto A; Weisel K; Ludwig H; Bahlis NJ; Banos A; Tiab M; Delforge M; Cavenagh JD; Geraldes C; Lee JJ; Chen C; Oriol A; De La Rubia J; White D; Binder D; Lu J; Anderson KC; Moreau P; Attal M; Perrot A; Arnulf B; Qiu L; Roussel M; Boyle E; Manier S; Mohty M; Avet-Loiseau H; Leleu X; Ervin-Haynes A; Chen G; Houck V; Benboubker L; Hulin C
Blood; 2018 Jan; 131(3):301-310. PubMed ID: 29150421
[TBL] [Abstract][Full Text] [Related]
2. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T
Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118
[TBL] [Abstract][Full Text] [Related]
3. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
[TBL] [Abstract][Full Text] [Related]
4. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Hulin C; Belch A; Shustik C; Petrucci MT; Dührsen U; Lu J; Song K; Rodon P; Pégourié B; Garderet L; Hunter H; Azais I; Eek R; Gisslinger H; Macro M; Dakhil S; Goncalves C; LeBlanc R; Romeril K; Royer B; Doyen C; Leleu X; Offner F; Leupin N; Houck V; Chen G; Ervin-Haynes A; Dimopoulos MA; Facon T
J Clin Oncol; 2016 Oct; 34(30):3609-3617. PubMed ID: 27325857
[TBL] [Abstract][Full Text] [Related]
5. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Bahlis NJ; Corso A; Mugge LO; Shen ZX; Desjardins P; Stoppa AM; Decaux O; de Revel T; Granell M; Marit G; Nahi H; Demuynck H; Huang SY; Basu S; Guthrie TH; Ervin-Haynes A; Marek J; Chen G; Facon T
Leukemia; 2017 Nov; 31(11):2435-2442. PubMed ID: 28373701
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L; Dimopoulos MA; Dispenzieri A; Catalano J; Belch AR; Cavo M; Pinto A; Weisel K; Ludwig H; Bahlis N; Banos A; Tiab M; Delforge M; Cavenagh J; Geraldes C; Lee JJ; Chen C; Oriol A; de la Rubia J; Qiu L; White DJ; Binder D; Anderson K; Fermand JP; Moreau P; Attal M; Knight R; Chen G; Van Oostendorp J; Jacques C; Ervin-Haynes A; Avet-Loiseau H; Hulin C; Facon T;
N Engl J Med; 2014 Sep; 371(10):906-17. PubMed ID: 25184863
[TBL] [Abstract][Full Text] [Related]
8. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
[TBL] [Abstract][Full Text] [Related]
9. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
[TBL] [Abstract][Full Text] [Related]
12. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
[TBL] [Abstract][Full Text] [Related]
14. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
15. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Stewart AK; Jacobus S; Fonseca R; Weiss M; Callander NS; Chanan-Khan AA; Rajkumar SV
Blood; 2015 Sep; 126(11):1294-301. PubMed ID: 26157076
[TBL] [Abstract][Full Text] [Related]
16. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
18. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
19. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
20. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
Weisel K; Doyen C; Dimopoulos M; Yee A; Lahuerta JJ; Martin A; Travers K; Druyts E; Toor K; Abildgaard N; Lu J; Van Droogenbroeck J; Geraldes C; Petrini M; Voillat L; Voog E; Facon T
Leuk Lymphoma; 2017 Jan; 58(1):153-161. PubMed ID: 27124703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
